Silence Therapeutics plc (SLN) [Rocket]

Date Filed	Type	Description
08/14/2023	SC 13D/A	Griffiths Richard Ian reports a 26.6% stake in Silence Therapeutics plc
02/14/2023	SC 13G/A	TCG Crossover GP I, LLC reports a 5.9% stake in Silence Therapeutics plc
02/14/2023	SC 13G/A	Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
02/08/2023	SC 13G/A	Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
10/20/2022	SC 13D/A	Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
08/22/2022	SC 13G	Form SC 13G - Statement of acquisition of beneficial ownership by individuals:
08/19/2022	SC 13G	Form SC 13G - Statement of acquisition of beneficial ownership by individuals:
07/20/2022	SC 13D/A	Griffiths Richard Ian reports a 28.4% stake in Silence Therapeutics plc
06/15/2022	SC 13D	Griffiths Richard Ian reports a 27% stake in Silence Therapeutics plc
02/14/2022	SC 13G	Quested Robert reports a 7.8% stake in Silence Therapeutics plc
02/14/2022	SC 13G	Griffiths Richard Ian reports a 23% stake in Silence Therapeutics plc
02/10/2022	SC 13G/A	Lombard Odier Asset Management Corp reports a 11.6% stake in Silence Therapeutics plc
02/07/2022	SC 13G	Mallinckrodt plc reports a 5.6% stake in Silence Therapeutics plc
01/27/2022	SC 13G	GOLDMAN SACHS GROUP INC reports a 5.4% stake in SILENCE THERAPEUTICS PLC
02/17/2021	SC 13G	Keith Robert Napier reports a 13.7% stake in Silence Therapeutics plc
02/17/2021	SC 13G	Griffiths Richard Ian reports a 23.3% stake in Silence Therapeutics plc
02/17/2021	SC 13G	Quested Robert reports a 8.5% stake in Silence Therapeutics plc
02/12/2021	SC 13G	Lombard Odier Asset Management Corp reports a 12.2% stake in Silence Therapeutics plc
12/08/2017	SC 13D/A	Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
12/01/2017	SC 13D	Form SC 13D - General statement of acquisition of beneficial ownership:
01/13/2017	SC 13D	Form SC 13D - General statement of acquisition of beneficial ownership: